Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis Modulation & Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Fas/CD95/FAS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FAS ECD-Fc Fusion Protein Sequence Verified, High purity (>95%), Endotoxin <1EU/ug, HEK293 Expressed (Native Glycosylation) |
View FAS Products |
| Gene Delivery | FAS Promise-ORF Lentivirus Full-length ORF for stable cell line construction; preserves death domain conformation |
View FAS Products |
| Benchmark Ab | Anti-FAS Agonist Antibody (CH11-class Sequence) Recombinant positive control for apoptosis induction |
View FAS Products |
| Validator | FAS siRNA Set For knockdown verification and specificity controls |
View FAS Products |
| Related Target: Fas Ligand | FasL/CD95L Recombinant Protein Functional ligand for cross-linking and apoptosis assays |
View Fas Ligand Products |
| Related Target: TRAIL | TRAIL/Apo2L Protein Parallel death receptor pathway for selectivity screening |
View TRAIL Products |
| Related Target: Caspase-8 | Recombinant Caspase-8 Enzyme Downstream signaling validation |
View Caspase-8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species-specific toxicity screening (Hepatotoxicity risk) | Human/Cyno/Mouse FAS ortholog proteins available; Native cysteine-rich domain folding verified by mass spec; Endotoxin controlled |
| ALPS mutant mechanism studies | Mutant FAS proteins available (e.g., ΔEx7, Death Domain truncations); Sequence verified for dominant negative studies |
| Lack of Functional Controls | FasL recombinant protein (trimeric) included for positive apoptosis induction; Benchmark agonist antibodies (CH11-class) |
| False Positives in Binding Assays | Validated siRNA included for target-specificity confirmation; FAS-negative cell line controls available |
Live Fas/CD95/FAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Fas/CD95/FAS therapeutics is intensifying along two divergent vectors: agonism for resistant solid tumors (requiring tumor-restricted activation to avoid hepatotoxicity) and antagonism for neurodegenerative diseases (ALS, Alzheimer's) and autoimmune lymphoproliferative syndrome (ALPS). As first-generation systemic agonists failed due to liver toxicity, the next wave of R&D is targeting conditionally-activated antibodies, localized delivery systems, and soluble Fas decoy receptors for autoimmune indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAbs (Conditional) | Catalym (Alemcinal indirect), Academic Bi-specifics | Solid Tumors (chemo-resistant) | Apoptosis induction assay with hepatocyte toxicity panel (Need Full-length Lentivirus for native conformation) |
| FasL Inhibitors | Annexon (ANX005 - C1q pathway), Soluble Fas-Fc | ALS, Alzheimer's, ALPS | Ligand binding inhibition (Need high-affinity FAS ECD-Fc for SPR) |
| Decoy Receptors | APG101 (Fas-Fc fusion) | Glioblastoma, Autoimmune | Soluble FAS quantification (Need ECD standards for ELISA) |
| Gene Therapy | Ex vivo CAR-T Fas-knockdown | Hematologic Malignancies | FAS expression validation (Need Lentivirus for overexpression controls) |